Abstract
Psychosis can be brought on by a number of different substances such as alcohol, cannabis, sedatives, cocaine, stimulants, and hallucinogens. For some substances the psychosis is predominant in the acute phase (cannabis, cocaine, stimulants, and hallucinogens), but for others the withdrawal phase infers the heightened risk (alcohol and sedatives). Some drugs may also increase the risk of longer lasting psychotic disorders (cannabis and central stimulants), but it remains an area of dispute whether these drugs cause the primary psychosis or whether they precipitate psychosis in individuals who are already vulnerable. This chapter reviews the literature on this topic and gives advice on the treatment of acute and prolonged psychotic illness in relationship to drug use, including delirium tremens caused by withdrawal from alcohol or sedatives.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allen MH, Currier GW, Carpenter D et al (2005) The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract 1(11 Suppl):5–108
Amato L, Minozzi S, Davoli M (2011) Efficacy and safety of pharmacological interventions for the treatment of the alcohol withdrawal syndrome. Cochrane Database of Systematic reviews. doi: 10.1002/14651858.CD008537.
Andréasson S, Allebeck P, Engström A, Rydberg U (1987) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 8574:1483–1486
Baldacchino A, Hughes Z, Kehoe M et al (2012) Cannabis psychosis: examining the evidence for a distinctive psychopathology in a systematic and narrative review. Am J Addict 21(Suppl 1):S88–S98
Bell DS (1965) Comparison of amphetamine psychosis and schizophrenia. Br J Psychiatry 111:701–707
Bramness JG, Gundersen ØH, Guterstam J et al (2012) Amphetamine-induced psychosis–a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry 12:221
Caton CL, Drake RE, Hasin DS et al (2005) Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Arch Gen Psychiatry 62(2):137–145
Cole J, Kando J (1993) Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines. J Clin Psychiatry 54:49–61
Curran C, Byrappa N, McBride A (2004) Stimulant psychosis: systematic review. Br J Psychiatry 185:196–204
Degenhardt HW, Lynskey M (2003) Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend 71:37–48
Grelotti DJ, Kanayama G, Pope HG Jr (2010) Remission of persistent methamphetamine-induced psychosis after electroconvulsive therapy: presentation of a case and review of the literature. Am J Psychiatry 167(1):17–23
Hedges DW, Woon FL, Hoopes SP (2009) Caffeine-induced psychosis. CNS Spectr 14:127–129
Hickman M, Vickerman P, Macleod J et al (2009) If cannabis caused schizophrenia–how many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations. Addiction 104:1856–1861
Johns A (2001) Psychiatric effects of cannabis. Br J Psychiatry 178:116–122
Koskinen J, Löhönen J, Koponen H et al (2010) Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull 36(6):1115–1130
Leamon MH, Flower K, Salo RE et al (2010) Methamphetamine and paranoia: the methamphetamine experience questionnaire. Am J Addict 19(2):155–168
Leelahanaj T, Kongsakon R, Netrakom P (2005) A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. J Med Assoc Thai 88(Suppl 3):S43–S52
McIver C, McGregor C, Baigant M et al (2006) Guidelines for the medical management of patients with methamphetamine psychosis. Drug and Alcohol Services, South Australia
Medhus S, Mordal J, Holm B et al (2013) A comparison of symptoms and drug use between patients with methamphetamine associated psychoses and patients diagnosed with schizophrenia in two acute psychiatric wards. Psychiatry Res 206:17–21
Moore TH, Zammit S, Lingford-Hughes A et al (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370:319–328
Núñez LA, Gurpegui M (2002) Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia. Acta Psychiatr Scand 105(3):173–178
Shoptaw SJ, Kao U, Ling W (2009) Treatment for amphetamine psychosis. Cochrane Database Syst Rev (1):CD003026
Srisurapanont M, Arunpongpaisal S, Wada K et al (2011) Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysis. Prog Neuropsychopharmacol Biol Psychiatry 35(4):959–964
Stone JM, Fisher HL, Major B et al (2013) Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation. Psychol Med 24:1–8
Sullivan JT, Sykora K, Schneiderman J et al (1989) Assessment of Alcohol Withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 84(11):1353–1357
Ujike H, Sato M (2004) Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann N Y Acad Sci 1025:279–287
Yeh HS, Lee YC, Sun HJ, Wan SR (2001) Six months follow-up of patients with methamphetamine psychosis. Zhonghua Yi Xue Za Zhi (Taipei) 64:388–394
Zammit S, Allebeck P, Andreasson S et al (2002) Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325:1199
Zuardi AW, Crippa JA, Hallak JE et al (2012) A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharm Des 18:5131–5140
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Bramness, J.G., Franck, J. (2015). Substance-Induced Psychotic Symptoms. In: Dom, G., Moggi, F. (eds) Co-occurring Addictive and Psychiatric Disorders. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45375-5_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-45375-5_7
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-45374-8
Online ISBN: 978-3-642-45375-5
eBook Packages: MedicineMedicine (R0)